Three Leading Growth Companies Insiders Are Investing In

As global markets navigate the complexities of tariff uncertainties and mixed economic signals, investors are keenly observing how these factors influence growth prospects across various sectors. Amidst this backdrop, companies with high insider ownership often attract attention, as insiders' investments can signal confidence in a company's potential to thrive despite market challenges.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Archean Chemical Industries (NSEI:ACI)	22.9%	50.8%
Seojin SystemLtd (KOSDAQ:A178320)	32.1%	39.9%
Clinuvel Pharmaceuticals (ASX:CUV)	10.4%	26.2%
SKS Technologies Group (ASX:SKS)	29.7%	24.8%
Pricol (NSEI:PRICOLLTD)	25.4%	25.2%
Medley (TSE:4480)	34.1%	27.3%
Plenti Group (ASX:PLT)	12.7%	120.1%
HANA Micron (KOSDAQ:A067310)	18.3%	119.4%
Fulin Precision (SZSE:300432)	13.6%	71%
Findi (ASX:FND)	35.8%	111.4%

Click here to see the full list of 1453 stocks from our Fast Growing Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Shanghai Runda Medical Technology (SHSE:603108)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Shanghai Runda Medical Technology Co., Ltd. operates in the medical technology sector, focusing on providing diagnostic and healthcare solutions, with a market cap of CN¥12.32 billion.

Operations: I apologize, but it seems there is no specific revenue segment information provided for Shanghai Runda Medical Technology in the text you shared. If you have more detailed data on their revenue segments, I would be happy to help summarize it.

Insider Ownership: 16%

Revenue Growth Forecast: 13.6% p.a.

Shanghai Runda Medical Technology demonstrates potential as a growth company with high insider ownership, despite recent profit margin declines from 4.1% to 0.5%. While the company's debt coverage by operating cash flow is inadequate and share price volatility persists, its earnings are projected to grow significantly at 67.16% annually over the next three years, surpassing the market's average growth rate of 25.3%. The stock is considered good value relative to peers and industry standards.

• Get an in-depth perspective on Shanghai Runda Medical Technology's performance by reading our analyst estimates report here.
• In light of our recent valuation report, it seems possible that Shanghai Runda Medical Technology is trading behind its estimated value.

Servyou Software Group (SHSE:603171)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Servyou Software Group Co., Ltd. offers financial and tax information services in China, with a market cap of CN¥17.36 billion.

Operations: Revenue Segments (in millions of CN¥): Financial and tax information services: 1,200; Software development: 800; IT consulting: 500.

Insider Ownership: 22.8%

Revenue Growth Forecast: 20.7% p.a.

Servyou Software Group shows potential despite lower profit margins, declining from 8.6% to 5%. Its earnings are forecasted to grow significantly at 55.4% annually over the next three years, outpacing the CN market's growth rate of 25.3%. Revenue is expected to rise by more than 20% annually, exceeding market averages. However, its share price has been highly volatile recently and return on equity is projected to remain low at 14.7%.

• Click here to discover the nuances of Servyou Software Group with our detailed analytical future growth report.
• Our comprehensive valuation report raises the possibility that Servyou Software Group is priced higher than what may be justified by its financials.

China Transinfo Technology (SZSE:002373)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: China Transinfo Technology Co., Ltd. operates in the transportation and IoT sectors with a market cap of CN¥16.22 billion.

Operations: China Transinfo Technology Co., Ltd. generates revenue primarily from its operations in the transportation and Internet of Things sectors.

Insider Ownership: 17.2%

Revenue Growth Forecast: 14.7% p.a.

China Transinfo Technology demonstrates strong growth potential with earnings having grown by a very large amount over the past year and forecasted to increase significantly at 58.11% annually, surpassing the CN market's expected growth of 25.3%. Despite a slower revenue growth rate of 14.7% per year compared to some peers, it remains above the market average. The company's price-to-earnings ratio of 69.1x is competitive within its industry, although return on equity is projected to be modest at 5.1%.

• Take a closer look at China Transinfo Technology's potential here in our earnings growth report.
• Upon reviewing our latest valuation report, China Transinfo Technology's share price might be too optimistic.

Next Steps

• Embark on your investment journey to our 1453 Fast Growing Companies With High Insider Ownership selection here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com